COHANCE LIFESCIENCES Financial Statement Analysis
|
||
|
The Revenues of COHANCE LIFESCIENCES have increased by 148.11% YoY .
The Earnings Per Share (EPS) of COHANCE LIFESCIENCES has decreased by -75.55 % YoY. |
||
COHANCE LIFESCIENCES Last 5 Annual Financial Results
[BOM: 543064|NSE : COHANCE]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹2,609 Cr | ₹1,051 Cr | ₹134,033 Cr | ₹1,320 Cr | ₹1,010 Cr |
| Expenses | ₹1,811 Cr | ₹646 Cr | ₹76,617 Cr | ₹739 Cr | ₹567 Cr |
| Operating Profit (Excl OI) | ₹797 Cr | ₹406 Cr | ₹57,416 Cr | ₹582 Cr | ₹443 Cr |
| Other Income | ₹69 Cr | ₹62 Cr | ₹4,636 Cr | ₹92 Cr | ₹14 Cr |
| Interest | ₹41 Cr | ₹7.45 Cr | ₹1,281 Cr | ₹8.53 Cr | ₹12 Cr |
| Depreciation | ₹167 Cr | ₹55 Cr | ₹4,799 Cr | ₹39 Cr | ₹32 Cr |
| Profit Before Tax | ₹643 Cr | ₹406 Cr | ₹55,973 Cr | ₹668 Cr | ₹468 Cr |
| Profit After Tax | ₹484 Cr | ₹300 Cr | ₹41,129 Cr | ₹454 Cr | ₹362 Cr |
| Consolidated Net Profit | ₹487 Cr | ₹300 Cr | ₹41,129 Cr | ₹454 Cr | ₹362 Cr |
| Earnings Per Share (Rs) | ₹4.68 | ₹19.14 | ₹11.79 | ₹16.16 | ₹17.83 |
| PAT Margin (%) | 6.62 | 18.56 | 28.56 | 30.66 | 34.35 |
| ROE(%) | 4.02 | 17.25 | 15.87 | 25.21 | 33.52 |
| ROCE(%) | 6.12 | 22.80 | 21.22 | 33.41 | 45.92 |
| Total Debt/Equity(x) | 0.04 | 0.07 | 0.02 | 0.04 | 0.06 |
Key Financials |
||
| Market Cap | : | ₹ 17,272.5 Cr |
| Revenue (TTM) | : | ₹ 2,141.5 Cr |
| Net Profit(TTM) | : | ₹ 58.5 Cr |
| EPS (TTM) | : | ₹ 1.5 |
| P/E (TTM) | : | 295.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| COHANCE LIFESCIENCES | -1.7% | -1.8% | -50.7% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.4% | -6.2% | 11.8% |
| DIVIS LABORATORIES | -3.3% | 1.4% | 57.4% |
| TORRENT PHARMACEUTICALS | -4.5% | -4% | 35.9% |
| CIPLA | -3.6% | -5% | -10.6% |
| DR REDDYS LABORATORIES | -0.2% | 2.5% | -3% |
| MANKIND PHARMA | 2.1% | 7.1% | -0.6% |
| LUPIN | -2.9% | -5.6% | 4.1% |
| ZYDUS LIFESCIENCES | -4.7% | -1.6% | 14.2% |
COHANCE LIFESCIENCES Revenues
[BOM: 543064|NSE : COHANCE]
| Y-o-Y | 148.11 % |
| 5 Yr CAGR | 26.78 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹2,609 Cr | 148.11 | |
| Mar2025 | ₹1,051 Cr | -99.22 | |
| Mar2024 | ₹134,033 Cr | 10,052.30 | |
| Mar2023 | ₹1,320 Cr | 30.75 | |
| Mar2022 | ₹1,010 Cr | - | |
COHANCE LIFESCIENCES Operating Profit
[BOM: 543064|NSE : COHANCE]
| Y-o-Y | 96.41 % |
| 5 Yr CAGR | 15.82 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹797 Cr | 96.41 | |
| Mar2025 | ₹406 Cr | -99.29 | |
| Mar2024 | ₹57,416 Cr | 9,770.06 | |
| Mar2023 | ₹582 Cr | 31.31 | |
| Mar2022 | ₹443 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -20.83 % |
| 5 Yr CAGR | -8.64 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 30.56% | -20.83 | |
| Mar2025 | 38.6% | -9.90 | |
| Mar2024 | 42.84% | -2.77 | |
| Mar2023 | 44.06% | 0.43 | |
| Mar2022 | 43.87% | - | |
COHANCE LIFESCIENCES Profit After Tax
[BOM: 543064|NSE : COHANCE]
| Y-o-Y | 62.30 % |
| 5 Yr CAGR | 7.69 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹487 Cr | 62.30 | |
| Mar2025 | ₹300 Cr | -99.27 | |
| Mar2024 | ₹41,129 Cr | 8,963.15 | |
| Mar2023 | ₹454 Cr | 25.24 | |
| Mar2022 | ₹362 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -64.33 % |
| 5 Yr CAGR | -33.74 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 6.62 % | -64.33 | |
| Mar2025 | 18.56 % | -35.01 | |
| Mar2024 | 28.56 % | -6.85 | |
| Mar2023 | 30.66 % | -10.74 | |
| Mar2022 | 34.35 % | - | |
COHANCE LIFESCIENCES Earnings Per Share (EPS)
[BOM: 543064|NSE : COHANCE]
| Y-o-Y | -75.55 % |
| 5 Yr CAGR | -28.42 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹4.68 | -75.55 | |
| Mar2025 | ₹19 | 62.34 | |
| Mar2024 | ₹12 | -27.04 | |
| Mar2023 | ₹16 | -9.37 | |
| Mar2022 | ₹18 | - | |
COHANCE LIFESCIENCES Return on Capital Employed (ROCE)
[BOM: 543064|NSE : COHANCE]
| Y-o-Y | -73.16 % |
| 5 Yr CAGR | -39.58 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 6.12% | -73.16 | |
| Mar2025 | 22.8% | 7.45 | |
| Mar2024 | 21.22% | -36.49 | |
| Mar2023 | 33.41% | -27.24 | |
| Mar2022 | 45.92% | - | |
COHANCE LIFESCIENCES Share Price vs Sensex
| Current Share Price | : | ₹451.5 |
| Current MarketCap | : | ₹ 17,272.5 Cr |
| Updated EOD on | : | Oct 01,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| COHANCE LIFESCIENCES | -1.7% |
-1.8% |
-50.7% |
| SENSEX | -2.3% |
-6.6% |
-12% |
COHANCE LIFESCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 1000 | -2.9% | -6.2% | -5% |
| BSE 500 | -3% | -6.5% | -6% |
| BSE 250 SMALLCAP INDEX | -3.3% | -4.4% | 0.7% |
| BSE 400 MIDSMALLCAP INDEX | -3.6% | -6.5% | -0.3% |
| BSE HEALTHCARE | -3.8% | -3.2% | 12.6% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP 500 | -2.7% | -3.7% | NA |
| NIFTY500 SHARIAH | -2.8% | -7.1% | -7.7% |
| NIFTY TOTAL MARKET | -3% | -6.6% | -5.1% |
| NIFTY 500 | -3.1% | -6.8% | -5.7% |
| NIFTY SMALLCAP 50 | -3.1% | -4.1% | 9.7% |
You may also like the below Video Courses
FAQ about COHANCE LIFESCIENCES Financials
How the annual revenues of COHANCE LIFESCIENCES have changed ?
The Revenues of COHANCE LIFESCIENCES have increased by 148.11% YoY .
How the Earnings per Share (EPS) of COHANCE LIFESCIENCES have changed?
The Earnings Per Share (EPS) of COHANCE LIFESCIENCES has decreased by -75.55 % YoY .
Check out Intrinsic Value of Peers of COHANCE LIFESCIENCES
Compare Stock Analytics of Peers of COHANCE LIFESCIENCES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
